Abstract
The National Cholesterol Education Program Adult Treatment Panel guidelines have established low-density lipoprotein cholesterol (LDL-C) treatment goals, and secondary non-high-density lipoprotein (HDL)-C treatment goals for persons with hypertriglyceridemia. The use of lipid-lowering therapies, particularly statins, to achieve these goals has reduced cardiovascular disease (CVD) morbidity and mortality; however, significant residual risk for events remains. This, combined with the rising prevalence of obesity, which has shifted the risk profile of the population toward patients in whom LDL-C is less predictive of CVD events (metabolic syndrome, low HDL-C, elevated triglycerides), has increased interest in the clinical use of inflammatory and lipid biomarker assessments. Furthermore, the cost effectiveness of pharmacological intervention for both the initiation of therapy and the intensification of therapy has been enhanced by the availability of a variety of generic statins. This report describes the consensus view of an expert panel convened by the National Lipid Association to evaluate the use of selected biomarkers [C-reactive protein, lipoprotein-associated phospholipase A 2, apolipoprotein B, LDL particle concentration, lipoprotein(a), and LDL and HDL subfractions] to improve risk assessment, or to adjust therapy. These panel recommendations are intended to provide practical advice to clinicians who wrestle with the challenges of identifying the patients who are most likely to benefit from therapy, or intensification of therapy, to provide the optimum protection from CV risk.
| Original language | English |
|---|---|
| Pages (from-to) | 338-367 |
| Number of pages | 30 |
| Journal | Journal of Clinical Lipidology |
| Volume | 5 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 1 2011 |
Fingerprint
Keywords
- Apolipoprotein B
- C-reactive protein
- Lipoprotein subfractions
- Lipoprotein(a)
- Lipoprotein-associated phospholipase A2
- Low-density lipoprotein particle concentration
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Endocrinology, Diabetes and Metabolism
- Internal Medicine
- Nutrition and Dietetics
Cite this
Clinical utility of inflammatory markers and advanced lipoprotein testing : Advice from an expert panel of lipid specialists. / Davidson, Michael H.; Ballantyne, Christie M.; Jacobson, Terry A.; Bittner, Vera A.; Braun, Lynne T.; Brown, Alan S.; Brown, W. Virgil; Cromwell, William C.; Goldberg, Ronald B; McKenney, James M.; Remaley, Alan T.; Sniderman, Allan D.; Toth, Peter P.; Tsimikas, Sotirios; Ziajka, Paul E.; Maki, Kevin C.; Dicklin, Mary R.
In: Journal of Clinical Lipidology, Vol. 5, No. 5, 01.09.2011, p. 338-367.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical utility of inflammatory markers and advanced lipoprotein testing
T2 - Advice from an expert panel of lipid specialists
AU - Davidson, Michael H.
AU - Ballantyne, Christie M.
AU - Jacobson, Terry A.
AU - Bittner, Vera A.
AU - Braun, Lynne T.
AU - Brown, Alan S.
AU - Brown, W. Virgil
AU - Cromwell, William C.
AU - Goldberg, Ronald B
AU - McKenney, James M.
AU - Remaley, Alan T.
AU - Sniderman, Allan D.
AU - Toth, Peter P.
AU - Tsimikas, Sotirios
AU - Ziajka, Paul E.
AU - Maki, Kevin C.
AU - Dicklin, Mary R.
PY - 2011/9/1
Y1 - 2011/9/1
N2 - The National Cholesterol Education Program Adult Treatment Panel guidelines have established low-density lipoprotein cholesterol (LDL-C) treatment goals, and secondary non-high-density lipoprotein (HDL)-C treatment goals for persons with hypertriglyceridemia. The use of lipid-lowering therapies, particularly statins, to achieve these goals has reduced cardiovascular disease (CVD) morbidity and mortality; however, significant residual risk for events remains. This, combined with the rising prevalence of obesity, which has shifted the risk profile of the population toward patients in whom LDL-C is less predictive of CVD events (metabolic syndrome, low HDL-C, elevated triglycerides), has increased interest in the clinical use of inflammatory and lipid biomarker assessments. Furthermore, the cost effectiveness of pharmacological intervention for both the initiation of therapy and the intensification of therapy has been enhanced by the availability of a variety of generic statins. This report describes the consensus view of an expert panel convened by the National Lipid Association to evaluate the use of selected biomarkers [C-reactive protein, lipoprotein-associated phospholipase A 2, apolipoprotein B, LDL particle concentration, lipoprotein(a), and LDL and HDL subfractions] to improve risk assessment, or to adjust therapy. These panel recommendations are intended to provide practical advice to clinicians who wrestle with the challenges of identifying the patients who are most likely to benefit from therapy, or intensification of therapy, to provide the optimum protection from CV risk.
AB - The National Cholesterol Education Program Adult Treatment Panel guidelines have established low-density lipoprotein cholesterol (LDL-C) treatment goals, and secondary non-high-density lipoprotein (HDL)-C treatment goals for persons with hypertriglyceridemia. The use of lipid-lowering therapies, particularly statins, to achieve these goals has reduced cardiovascular disease (CVD) morbidity and mortality; however, significant residual risk for events remains. This, combined with the rising prevalence of obesity, which has shifted the risk profile of the population toward patients in whom LDL-C is less predictive of CVD events (metabolic syndrome, low HDL-C, elevated triglycerides), has increased interest in the clinical use of inflammatory and lipid biomarker assessments. Furthermore, the cost effectiveness of pharmacological intervention for both the initiation of therapy and the intensification of therapy has been enhanced by the availability of a variety of generic statins. This report describes the consensus view of an expert panel convened by the National Lipid Association to evaluate the use of selected biomarkers [C-reactive protein, lipoprotein-associated phospholipase A 2, apolipoprotein B, LDL particle concentration, lipoprotein(a), and LDL and HDL subfractions] to improve risk assessment, or to adjust therapy. These panel recommendations are intended to provide practical advice to clinicians who wrestle with the challenges of identifying the patients who are most likely to benefit from therapy, or intensification of therapy, to provide the optimum protection from CV risk.
KW - Apolipoprotein B
KW - C-reactive protein
KW - Lipoprotein subfractions
KW - Lipoprotein(a)
KW - Lipoprotein-associated phospholipase A2
KW - Low-density lipoprotein particle concentration
UR - http://www.scopus.com/inward/record.url?scp=80053914425&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053914425&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2011.07.005
DO - 10.1016/j.jacl.2011.07.005
M3 - Article
C2 - 21981835
AN - SCOPUS:80053914425
VL - 5
SP - 338
EP - 367
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
SN - 1933-2874
IS - 5
ER -